Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 9/20 | 1.00 |
| ▸ | CDK2 | P24941 | 9/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 7/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 5/20 | 1.00 |
| ▸ | CDK9 | P50750 | 5/20 | 1.00 |
| ▸ | CDK4 | P11802 | 3/20 | 1.00 |
| ▸ | CCND1 | P24385 | 3/20 | 1.00 |
| ▸ | CDK7 | P50613 | 3/20 | 1.00 |
| ▸ | CCNH | P51946 | 3/20 | 1.00 |
| ▸ | CDK1 | P06493 | 2/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 2/20 | 1.00 |
| ▸ | CCNT2 | O60583 | 1/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 1/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 1.00 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 7/20 | 0.71 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12589685 | 1.00 | CCNE1 (1.00) | CCNE1CDK2CCNE2CCNT1CDK9 | |
| SCHEMBL4882905 | 0.86 | CCNE1 (0.75) | CCNE1CDK2CCNE2CCNT1CDK9 | |
| SCHEMBL4882884 | 0.86 | CCNE1 (0.75) | CCNE1CDK2CCNE2CCNT1CDK9 | |
| SCHEMBL3837502 | 0.83 | CCNE1 (0.71) | CCNE1CDK2CCNE2CCNT1CDK9 | |
| SCHEMBL3836624 | 0.83 | MAPT (1.00) | CCNE1CDK2CCNE2CCNT1CDK9 | |
| SCHEMBL3836615 | 0.83 | MAPT (1.00) | CCNE1CDK2CCNE2CCNT1CDK9 | |
| SCHEMBL3839801 | 0.83 | GAA (1.00) | CCNE1CDK2CCNE2CCNT1CDK9 | |
| SCHEMBL3837703 | 0.83 | MAPT (0.71) | CCNE1CDK2CCNE2CCNT1CDK9 | |
| SCHEMBL3837556 | 0.82 | CCNE1 (1.00) | CCNE1CDK2CCNE2CCNT1CDK9 | |
| SCHEMBL3837559 | 0.82 | CCNE1 (1.00) | CCNE1CDK2CCNE2CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-12 | — | — | US | claimed |
| US-20240293557-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-09-05 | — | — | US | claimed |
| US-20230293414-A1 | USE OF CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS FOR THE SLOWDOWN OR PREVENTION OF BIOLOGICAL AGING | HOPE PERMANENTE LLC (US) | 2023-09-21 | — | — | US | claimed |
| EP-4192463-A1 | USE OF CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS FOR THE SLOWDOWN OR PREVENTION OF BIOLOGICAL AGING | Hope Permanente, LLC (US) | 2023-06-14 | — | — | EP | claimed |
| US-20230109457-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-06 | — | — | US | claimed |
| WO-2022266491-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-22 | — | — | WO | claimed |
| WO-2022261220-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-15 | — | — | WO | claimed |
| US-11351161-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-07 | — | — | US | claimed |
| CN-107904201-B | Differentiation of human embryonic stem cells into the pancreatic endocrine lineage | 詹森生物科技公司 | 2021-11-16 | — | — | CN | claimed |
| US-11020404-B2 | Use of CDK9 and BRD4 inhibitors to inhibit inflammation | The Regents of the University of California, Davis (US) | 2021-06-01 | — | — | US | claimed |
| US-20210008054-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-01-14 | — | — | US | claimed |
| US-10639302-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-05-05 | — | — | US | claimed |
| US-20200046726-A1 | USE OF CDK9 AND BRD4 INHIBITORS TO INHIBIT INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | claimed |
| US-20190255034-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-22 | — | — | US | claimed |
| US-10172844-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-08 | — | — | US | claimed |
| EP-2346988-B1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO THE PANCREATIC ENDOCRINE LINEAGE | JANSSEN BIOTECH INC (US) | 2017-05-31 | — | — | EP | claimed |
| EP-1786779-B1 | 4-ARYLAZO-3,5-DIAMINO-PYRAZOLE COMPOUNDS AND USE THEREOF | INST OF EX BOTANY OF THE ASCR (CZ) | 2009-10-28 | — | — | EP | claimed |
| US-20080312238-A1 | 4-Arylazo-3,5-Diamino-Pyrazole Compounds and Use Thereof | INSTITUTE OF EXPERIMENTAL BONTANY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC, V.V.I. (CZ) | 2008-12-18 | — | — | US | claimed |
| EP-1786779-A1 | 4-ARYLAZO-3,5-DIAMINO-PYRAZOLE COMPOUNDS AND USE THEREOF | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2007-05-23 | — | — | EP | claimed |
| WO-2006024858-A1 | 4-ARYLAZO-3,5-DIAMINO-PYRAZOLE COMPOUNDS AND USE THEREOF | INSTITUTE OF EXPERIMENTAL BOTANY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2006-03-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200046726-A1 | USE OF CDK9 AND BRD4 INHIBITORS TO INHIBIT INFLAMMATION | CDK9, BRD4, CDK19 | CCNE1 83/4885CDK2 11/4885CCNE2 116/4885 |
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | BCL3, MCL1, BCL2 | CCNE1 1783/4885CDK2 741/4885CCNE2 2719/4885 |
| US-11020404-B2 | Use of CDK9 and BRD4 inhibitors to inhibit inflammation | CDK9, BRD4, CDK19 | CCNE1 83/4885CDK2 11/4885CCNE2 116/4885 |
| US-20080312238-A1 | 4-Arylazo-3,5-Diamino-Pyrazole Compounds and Use Thereof | CDK9, CDK3, CDK19 | CCNE1 93/4885CDK2 13/4885CCNE2 279/4885 |
| US-20240293557-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | MCL1, BCL3, CRBN | CCNE1 1814/4885CDK2 1951/4885CCNE2 3867/4885 |
| US-20230109457-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | CDK9, CDK19, CDKN1A | CCNE1 53/4885CDK2 8/4885CCNE2 79/4885 |
| US-20210008054-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | CDK9, CDK19, CDKN1A | CCNE1 53/4885CDK2 8/4885CCNE2 79/4885 |
| US-20190255034-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | CDK9, CDK19, CDKN1A | CCNE1 53/4885CDK2 8/4885CCNE2 79/4885 |
| US-11351161-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | CDK9, CDK19, CDKN1A | CCNE1 53/4885CDK2 8/4885CCNE2 79/4885 |
| US-10172844-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | CDK9, CDK19, CDKN1A | CCNE1 53/4885CDK2 8/4885CCNE2 79/4885 |
| US-10639302-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | CDK9, CDK19, CDKN1A | CCNE1 53/4885CDK2 8/4885CCNE2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.